PRFX | PainReform
Next ER: May 12, 2022
PainReform is a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics. Our proprietary extended release drug-delivery system has the potential to prolong the in vivo activity of APIs (active pharmaceutical ingredients), thus increasing the therapeutic window for patient treatment. Our strategy is to incorporate generic drugs with our proprietary extended release drug-delivery system in order to create extended release drug products and to take advantage of the 505(b)(2) regulatory pathway created by the U.S. Food and Drug Administration (?FDA?).
This company doesn't provide a dividend.
Talk about PainReform below in comments section below.
Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above.
If you are looking for News & events, Press Release, they are available on their Investors Relationssite.
If you want to help pay for server cost or for improving this tool. You can send it via Paypal.
Buy on Amazon
Want to know the strategies of successful swing trading? This friendly guide covers the ins and outs of this risky but profitable investing approach, explaining all the basics in plain English. You'll see how to use the two investment approaches - technical and fundamental analysis - to indentify promising securities in strongly trending markets. In addition, this guide covers how to calculate investment returns and, most important, how to manage your portfolio's risk.
Take advantage of price swings in strongly trending securities and pump up your portfolio!